Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours:
Olema Oncology Receives FDA Fast Track Designation For OP-1250 For Treatment Of ER+ / HER2- Metastatic Breast Cancer
Olema Pharmaceuticals, Inc. ((&ldquo, Olema&rdquo, or &ldquo, Olema Oncology, &rdquo, NASDAQ:OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250, the
HC Wainwright & Co. Upgrades Olema Pharmaceuticals to Buy
HC Wainwright & Co. analyst Emily Bodnar upgrades Olema Pharmaceuticals (NASDAQ:OLMA) from Neutral to Buy.
69 Biggest Movers From Friday
Gainers
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
